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Background: Although several histopathological and clinical features of canine mammary gland tumours have
been widely studied from a prognostic standpoint, considerable variations in tumour individual biologic behaviour
difficult the definition of accurate prognostic factors. It has been suggested that the malignant behaviour of
tumours is the end result of several alterations in cellular physiology that culminate in tumour growth and spread.
Accordingly, the aim of this study was to determine, using a multivariable model, the independent prognostic
value of several immunohistochemically detected tumour-associated molecules, such as MMP-9 and uPA in stromal
cells and Ki-67, TIMP-2 and VEGF in cancer cells.
Results: Eighty-five female dogs affected by spontaneous malignant mammary neoplasias were followed up for a
2-year post-operative period. In univariate analysis, tumour characteristics such as size, mode of growth, regional
lymph node metastases, tumour cell MIB-1 LI and MMP-9 and uPA expressions in tumour-adjacent fibroblasts, were
associated with both survival and disease-free intervals. Histological type and grade were related with overall
survival while VEGF and TIMP-2 were not significantly associated with none of the outcome parameters. In
multivariable analysis, only a MIB-1 labelling index higher than 40% and a stromal expression of MMP-9 higher than
50% retained significant relationships with poor overall and disease-free survival.
Conclusions: The results of this study indicate that MMP-9 and Ki-67 are independent prognostic markers of
canine malignant mammary tumours. Furthermore, the high stromal expressions of uPA and MMP-9 in
aggressive tumours suggest that these molecules are potential therapeutic targets in the post-operative
treatment of canine mammary cancer.
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Mammary tumours are the most prevalent neoplasms in
intact female dogs [1] and it has been described that ap-
proximately 40 to 50% are histologically malignant [2].
Mammary cancers have, however, variable biological
behaviours, hampering estimates of individual clinical* Correspondence: ajmatos@icbas.up.pt
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reproduction in any medium, provided the oroutcomes based solely on their histological and clinical
characteristics [3].
Several studies reported that factors such as tumour
size [4,5], histological type [6], histological grade [7,8],
mode of growth [4,9] and lymph node status [10,11] in-
fluence the prognosis of canine malignant mammary
tumours (MMTs) and these factors are currently used in
practice to establish a prognosis. These clinical and
histological factors are, however, crude determinants and
are not used, in routine practice, as indicators of the
need for adjuvant post-operative therapies.
In human breast cancer, molecular markers (oestrogen
and progesterone receptors and c-erbB2) are routinelyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Histological classification of CMTs according to
World Health Organization and description of tumour
types with distant metastases
Histological Type Tumours Metastasized tumours
Number % Number %
Solid carcinomas 30 35.3 8 26.7
Complex carcinomas 20 23.5 4 20.0
Tubulopapillary carcinomas 18 21.2 5 27.7
Carcinosarcomas 9 10.6 3 33.3
Anaplastic carcinomas 2 2.4 1 50.0
Carcinomas in benign tumours 2 2.4 2 100
Mucinous carcinomas 2 2.4 1 50.0
Micropapillary carcinomas 1 1.1 1 100
Spindle cell carcinomas 1 1.1 1 100
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erinary medicine, although some potential prognostic
biomarkers have been investigated in canine MMTs,
such as proliferation markers [9,13], hormone receptors
[4,11,14,15] and oncogenes [5,16] none has been
adopted in the routine pathological processing of spon-
taneous malignant tumours. This is due, in part, to the
small number of prospective multivariable survival stud-
ies that demonstrated their prognostic value. Therefore,
the investigation of molecular markers with prognostic
and predictive value is still required in order to
recognize animals in need for adjuvant therapies, as well
as to identify new therapeutic targets.
Previously published studies investigated either the
characteristics of the tumour cells or those of the entire
tumour population (tumour cells and stroma), seldom
considering the tumour-stroma crosstalk by the individ-
ual characterization of the distinct cell types. However, it
has been demonstrated, in human breast cancer, that the
interactions between cancer cells and stroma are critical
for tumour growth and invasion [17]. There are increas-
ing evidences that both cancer and stromal cells interact
in a coordinated way to facilitate proliferation, invasion
and angiogenesis, by remodelling the tumour micro-
environment through matrix-associated proteases, such
as matrix metalloproteinases and serine proteases, that
breakdown basal membranes and proteins of the extra-
cellular matrix [18].
In this context, this study aimed to evaluate the prog-
nostic value of several clinical, histological and molecu-
lar features of canine MMTs, including angiogenic
factors (VEGF), matrix degrading proteins (uPA and
MMP-9), and proliferation markers (Ki-67), in a pro-
spective two-years follow up study. Factors significantly
related to outcome, identified in univariate analysis, were
included in a multivariable study in order to identify in-
dependent prognostic factors that may be adopted in
routine practice and constitute potential targets of adju-
vant therapies.
Results
The mean ± SD age of the dogs at the time of surgery
was 10.3 ± 2.9 years (range 5–15). Thirteen dogs were
spayed before or at the time of surgery. Only 8 had
received hormonal therapy for oestrous prevention.
The tumour histological types and the corresponding
development of recurrences and/or distant metastases
are presented in Table 1.
Overall, 30% of the dogs developed recurrences or dis-
tant metastases and 25.8% died or were euthanized due to
this feature during the follow-up period. The mean ± SD
survival time for dogs with recurrence/distant metastases
was 11.96 ± 7.58 months (range 2–24) and the mean time
for the detection of recurrence/metastasis was 5.29 ±5.68 months (range 1–21). The overall 2-year survival
was 48%. Within patients that developed recurrences or
distant metastases, 38.5% had been spayed and 25% had
been treated in the past with progestagens-based therapy
for oestrus control.
Host factors were not associated with disease-free sur-
vival (DFS) or overall survival (OS) (Table 2), but the
mean DFS and OS tended to decrease in the largest
breeds. In spite of the small numbers, neither reproduct-
ive status nor hormonal therapy significantly influenced
OS and DFS.
Animals with complex carcinomas presented longer
survival times and lower risk of death caused by
MMT, when compared to the “others” group but not
to those with simple carcinomas (Tables 2 and 3). No
relationships were found between ulceration, necrosis
or squamous metaplasia and OS or DFS. Larger
tumours (≥ 3 cm) and tumours with invasive growth
were associated to shorter DFS (Table 2; Figure 1) and
OS (Table 2; Figure 2), an increased risk to the devel-
opment of recurrences/distant metastases (Table 4)
and to cause death due to MMT (Table 3). Grade III
tumours were associated with shorter OS (Table 2;
Figure 2) and increased risk of related death (Table 3).
Mitotic index was not related with patient survival
(Table 2). Regional lymph node (RLN) metastases were
significantly associated with shorter OS and DFS times
(Table 2), increased risk of recurrence/distant metasta-
sis (HR: 2.8; 95% CI: 1.13-6.91; P = 0.025) and related
death (HR: 3.56; 95% CI: 1.37-9.26; P = 0.009).
The mean ± SD MIB-1 labelling index (LI) was 39.6 ±
2.0 percent (range 6.5- 84.2). Factors significantly related
to shorter DFS, shorter OS, tumour-related death and
higher risk of recurrences/distant metastases included
high MIB-1 LI and high uPA and MMP-9 expressions by
tumour-adjacent fibroblasts (Tables 2 and 3; Figures 1
and 3). VEGF and TIMP-2 expressions were not asso-
ciated with DFS or OS (Table 2).
Table 2 Association between studied variables with disease-free and overall survival times









N % N % (± SE) N % (± SE)
Total 85 100 26 30.6 5.3 (5.7) 22 25.8 11.9 (7.6)
Animal factors
Weight (kg) NS NS
<10 27 31.8 7 25.9 19.6 (1.6) 6 22.2 21.7 (1.2)
10-23 39 45.9 11 28.2 18.3 (1.5) 10 25.6 20.0 (1.2)
>23 19 22.3 8 42.1 15.8 (2.2) 6 31.6 19.2 (1.8)
Spayed NS NS
No 72 84.7 21 29.2 18.4 (1.1) 17 23.6 20.7 (0.8)
Yes 13 15.3 5 38.5 16.8 (2.7) 5 38.5 19.3 (1.9)
Hormonal therapyb NS NS
No 74 90.2 23 31.1 18.0 (1.1) 19 25.7 20.5 (0.8)
Yes 8 9.8 2 25.0 19.5 (2.9) 2 25.0 20.7 (2.4)
Tumour factors
Ulceration NS NS
No 74 87.1 21 28.4 18.6 (1.0) 17 23.0 21.0 (0.8)
Yes 11 12.9 5 45.5 14.6 (3.2) 5 45.5 16.6 (2.8)
Size 0.027 0.016
< 3 cm 47 55.3 10 21.3 20.3 (1.1) 8 17.0 22.1 (0.8)
≥ 3 cm 38 44.7 16 42.1 15.5 (1.7) 14 36.8 18.3 (1.3)
Necrosis NS NS
No 25 29.4 7 28.0 18.3 (1.9) 7 28.0 20.1 (1.5)
Yes 60 70.6 19 31.2 18.0 (1.2) 15 25.0 20.5 (0.9)
Squamous metaplasia NS NS
No 62 72.9 19 30.1 18.1 (1.2) 17 27.4 20.5 (0.9)
Yes 23 27.1 7 30.4 18.1 (1.9) 5 21.7 20.4 (1.6)
Mode of growth 0.007 0.022
Expansive 24 28.2 2 8.3 22.6 (0.9) 2 8.3 23.3 (0.7)
Invasive 61 71.8 24 39.3 16.4 (1.3) 20 32.8 19.3 (0.9)
Histological type NS 0.023
Complex carcinomas 20 23.5 4 20.0 20.7 (1.6) 2 10.0 23.6 (0.3)
Simple carcinomas 51 60.0 15 29.4 18.5 (1.3) 13 25.5 20.6 (0.9)
Others 14 16.5 7 50.0 13.1 (2.9) 7 50.0 15.4 (2.4)
Mitotic index NS NS
0-9/10hpf 36 42.4 10 27.8 18.6 (1.5) 9 25.0 20.9 (1.2)
10-19/10hpf 25 29.4 6 24.0 18.9 (1.8) 4 16.0 21.2 (1.3)
≥ 20/10hpf 24 28.2 10 41.7 16.7 (1.9) 9 37.5 19.1 (1.4)
Histological grade NS 0.025
I + II 58 68.2 14 24.1 19.3 (1.1) 11 19.0 21.8 (0.8)
III 27 31.8 12 44.4 15.5 (1.9) 11 40.7 17.7 (1.6)
RLN metastasesa 0.017 0.005
No 47 71.2 10 21.3 20.2 (1.1) 8 17.0 22.2 (0.7)
Yes 19 28.8 9 47.4 14.6 (2.4) 9 47.4 17.3 (2.1)
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Table 2 Association between studied variables with disease-free and overall survival times (Continued)
Cancer cells
MIB1 L.I. (%) <0.001 <0.001
< 40 47 55.3 7 14.9 21.1 (1.03) 6 12.8 22.8 (0.7)
≥ 40 38 44.7 19 50.0 14.4 (1.66) 16 42.1 17.5 (1.4)
TIMP-2 (%) NS NS
< 25 32 37.6 7 21.9 19.7 (1.5) 5 15.6 21.6 (1.1)
≥ 25 53 62.4 19 35.8 17.1 (1.3) 17 32.1 19.7 (1.0)
VEGF-A (%) NS NS
< 50 47 55.3 14 29.8 18.4 (1.3) 10 21.3 21.1 (0.9)
≥ 50 38 44.7 12 31.6 17.7 (1.5) 12 31.6 19.7 (1.0)
Stromal cells
uPA (%) 0.016 0.012
< 10 25 29.4 3 12.0 21.9 (1.1) 2 8.0 23.5 (0.4)
≥ 10 60 70.6 23 38.3 16.5 (1.3) 20 33.3 19.1 (1.0)
MMP-9 (%) <0.001 <0.001
< 50 54 63.5 9 16.7 20.9 (0.9) 8 14.8 22.5 (0.7)
≥ 50 31 36.5 17 54.8 13.2 (1.9) 14 45.2 16.7 (1.5)
a Lymph nodes were not submitted in 19 cases.
b The information regarded hormonal therapy was impossible to obtain in three cases.
*Log Rank test.
NS – not significant.
Table 3 Prognostic factors significantly associated with overall survival
Variable Univariate Multivariable*
Hazard ratio 95% CI P Hazard ratio 95% CI P
Tumour size
< 3 cm Referent
≥ 3 cm 2.79 1.16-6.68 0.022 NS
Mode of growth
Expansive Referent
Invasive 4.63 1.08-19.85 0.039 NS
Histological type
Complex carcinomas Referent
Simple carcinomas 2.75 0.62-12.17 NS
Others 6.48 1.34-31.22 0.020 NS
Histological grade
I + II Referent
III 2.52 1.09-5.82 0.031 NS
MIB1 L.I. (%)
< 40 Referent Referent
≥ 40 4.60 1.79-11.85 0.002 4.06 1.56-10.58 0.004
uPA (%)
< 10 Referent
≥ 10 5.28 1.23-22.60 0.025 NS
MMP-9 (%)
< 50 Referent Referent
≥ 50 4.21 1.76-1.09 0.001 3.67 1.52-8.89 0.004
* Cox proportional hazard model: forward stepwise method – likelihood ratio.
NS – not significant.
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Figure 1 Kaplan-Meier disease free survival curves comparing immunohistochemical clinico-pathological factors in 85 dogs with
MMTs. Female dogs with tumours larger than 3 cm, invasive growth, MIB-1 labelling index higher than 40%, and high uPA and MMP-9
immunoexpressions in stromal cells had significantly shorter disease-free intervals.
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LI (≥40%) and high MMP-9 expression by stromal fibro-
blasts (≥ 50%) were the only factors that retained statis-
tical significance as independent predictors of shorter
DFS (Table 4) and OS (Table 3).
Discussion
In this study host related factors such as weight, repro-
ductive status and hormonal therapies were not signifi-
cantly related to patient outcomes. Although these
conclusions are in agreement with previous studies
[4,10,19,20], the lack of influence of the reproductive
status and hormonal therapies must be regarded with
caution since only six animals were spayed at the time of
mastectomy and only eight had received oestrous con-
trol therapy.
Some prognostic studies suggested that there is an in-
creasing malignancy from complex carcinomas to simple
carcinomas to sarcomas [3,6,16,21], although this factwas not demonstrated in other publications [4,20,22]. In
this study, considering the most frequent histological
types (number > 5), carcinosarcomas were the most ag-
gressive tumours (33% local recurrences and/or distant
metastases), while complex carcinomas were the less ag-
gressive ones (20% local recurrences and/or distant me-
tastases and significantly lower risk of death due to
MMTs). The differences between simple carcinomas and
the other groups were not significant, demonstrating that
solid and tubulopapillary carcinomas are probably an het-
erogeneous group of neoplasms, with distinct invasive and
metastatic capacities equally distributed among both
groups, as demonstrated by the very similar percentages of
local recurrences and/or distant metastases (26.7% for solid
and 27.7% for tubulopapillary carcinomas).
Ulceration and necrosis, two features that have been
suggested to be indicators of higher tumour aggressive-
ness [4,6,10], were not significantly related to prognosis
in this study. Although ulceration may be caused by the
Figure 2 Kaplan-Meier overall survival curves comparing clinical and histopathological parameters in 85 dogs with MMTs. Dogs with
tumours smaller than 3 cm, with expansive growth, well to moderately differentiated and classified as complex carcinomas had significantly
longer survival times.
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may also be due to self-induced trauma, skin ischemia
or infection, features that are not necessarily associated
to an aggressive biological behaviour. In a previous study
[4], necrosis was associated to poorer outcome but dif-
ferent assessment methodologies may explain the diver-
gent results.
Although squamous metaplasia is often regarded as
a sign of tumour aggressiveness in human breast can-
cer [23,24], this is the first study in canine mammary
tumours (CMTs) to address it as an independent vari-
able and, contradicting the previous notion, squamous
metaplasia failed to demonstrate a significant prog-
nostic value.
Corroborating previous findings [2,7,10,15], our study
showed that histological grade might be helpful to pre-
dict survival time, although not time to recurrence or
metastasis. It must be remembered, however, that several
grading methods have been used to classify MMTs indogs. The Nottingham method is, in the authors’ opin-
ion, a well standardized method that, although devel-
oped for human breast cancer, is applicable to canine
MMTs and, as these results demonstrate, associated to
survival time.
High MIB-1 LI were strongly associated to the devel-
opment of recurrences/distant metastases as well as with
shorter DFS and OS intervals, both in univariate and
multivariable analysis. Half of the animals bearing
tumours with LI higher than 40% developed local recur-
rences and/or distant metastasis and 42% died within
2 years after surgery. Previous CMTs studies associated
higher MIB-1 LI with other aggressive tumour features
(larger size [5,13], infiltrative growth [6], high histo-
logical grade [13]), higher risk of metastatic disease [11]
and decreased DFS and OS [7,9], strengthening our find-
ings. Other multivariable studies, however, reported op-
posite results [9,22,25], which may be explained by the
small number of cases studied in the Lee et al. (2004)
Table 4 Prognostic factors significantly associated with disease free survival
Variable Univariate Multivariable*
Hazard ratio 95% CI P Hazard ratio 95% CI P
Tumour size
< 3 cm Referent
≥ 3 cm 2.33 1.06-5.14 0.036 NS
Mode of growth
Expansive Referent
Invasive 5.62 1.33-23.80 0.019 NS
MIB1 L.I. (%)
< 40 Referent Referent
≥ 40 4.15 1.74-9.90 0.001 3.24 1.35-7.78 0.009
uPA (%)
< 10 Referent
≥ 10 3.82 1.14-12.72 0.029 NS
MMP-9 (%)
< 50 Referent Referent
≥ 50 4.34 1.93-9.77 <0.001 3.38 1.49-7.67 0.004
*Cox regression model: forward stepwise method – likelihood ratio.
NS - not significant.
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gies between studies. Our methodology consisted in the
evaluation of the highest labelled areas. When compared
to the previously described counting in 3–5 randomized
fields [22], our method eases the work of the observer,
reduces variability between samples, and allows a more
rigorous comparison between large tumours, where it is
easier to find suitable non-overlapping fields, and smaller
ones, where the choice of fields is more limited. Mitotic
index, frequently used to assess tumour proliferative ac-
tivity, was not associated to patient prognosis in this
series. Therefore, it seems that MIB-1 it is a more suit-
able proliferation-associated prognostic indicator than
mitotic index.
The presence of RLN metastases was associated to an
increased risk for the development of recurrence or dis-
tant metastases and tumour-associated death in univari-
ate analysis. Unfortunately, it was not possible to
demonstrate its value as an independent prognostic fac-
tor in multivariable analysis because RLN were not sur-
gically removed in 19 (22%) cases. Apparently, as
demonstrated by previous studies, this variable fails to
maintain its prognostic significance when included in
multivariable models [4,6].
In human breast cancer studies, it has been proposed
that the expression of VEGF by cancer cells is a poor
prognostic factor for survival [26], but this hypothesis
was contested by other studies [27,28]. To the best of our
knowledge, there is only one previous CMTs survival
study that addressed VEGF expression [29] and reported
it not to be associated with OS. Our findings demon-
strate that VEGF expression by cancer cells is notassociated with either OS or DFS, suggesting that this
angiogenic factor is not useful as a prognosticator of ca-
nine MMTs. Recently, Al-Dissi et al. (2010) [30] verified
that there were no correlations between the expression
of VEGF, its receptor-2 and tumour microvascular dens-
ity, suggesting that other factors are more important than
VEGF in CMTs angiogenesis. Furthermore, it has been
suggested that VEGF could be an early carcinogenic fac-
tor that declines with malignant progression [31], a hy-
pothesis that may justify our results.
The protein TIMP-2, initially described as an inhibitor
and regulator of the activity of matrix metalloproteinase-
2 (MMP-2), has recently been proven to stimulate cell
growth and angiogenesis, as well as inhibit apoptosis,
hence contributing to tumour aggressiveness [32]. Al-
though no other CMTs study groups assessed the prog-
nostic value of TIMP-2 expression, human breast cancer
studies revealed that high levels of TIMP-2 mRNA and
TIMP-2 protein are correlated with the development of
distant metastasis and decreased DFS [33,34]. In the
present study, the quantitative expression of TIMP-2 (i.e.
number of positive cells) was not related to outcome. Al-
though this may seem in contradiction with our previous
results [35] it must be noticed that the expression of the
molecule was evaluated, in that study, using a score
obtained by evaluating both number and intensity of ex-
pression. However, the reproducibility of intensity scales
is very difficult in the routine setting. Therefore, we
decided to use a more reproducible classification system
in this study.
An increasing number of studies over the last decade
identified the tumour stroma as a major player of the
Figure 3 Kaplan-Meier overall survival curves comparing several immuno-histochemical factors in 85 dogs with MMTs. MIB-1 labelling
index higher than 40%, and increased MMP-9 and uPA immunoexpressions predicted poorer survival times.
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invasion, cancer cells interact with their microenviron-
ment to activate signalling pathways and to increase
growth factors bioavailability, thus favouring tumour
progression [18]. Stromal proteases, such as MMPs and
uPA, are frequently upregulated in tumour microenvir-
onment and influence tumour behaviour by tissue archi-
tecture disruption and signalling interactions [17]. We
demonstrated that stromal expressions of both uPA andMMP-9 were associated to poorer outcomes in univari-
ate study, although only MMP-9 was able to maintain its
independent prognostic value in multivariable analysis.
We also verified that stromal expressions of uPA and
MMP-9 are highly associated, which may justify why
uPA lost significance in the multivariable model that
included MMP-9. To the best of our knowledge, this is
the first multivariable survival study addressing these
stromal markers in canine MMTs.
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The results of this study demonstrate that the expres-
sions of MMP-9 by stromal cells and of Ki-67 by cancer
cells are independent prognostic factors in canine
MMTs, that may be used for the selection of those ani-
mals that should be considered for post-operative ancil-
lary treatments. These factors exhibited a stronger
prognostic value than clinical or histological parameters
traditionally used to predict patient’s outcome, such as
tumour size, histological grade and mode of growth.
Hence, we suggest that they should be considered in the
routine prognostic assessment to help practitioners in
the prediction of patients’ outcome.
In addition, our findings highlight the role of tumour
stroma in the biological behaviour of canine MMTs and




Eighty-five female dogs with spontaneous MMTs
underwent surgical treatment and were enrolled, with
owners consent, in a 2-year post-operative follow-up
study. The study protocol was performed in compli-
ance with the European Union Directives for the pro-
tection of animals used for scientific purposes (1999/
575/CE and 2010/63/UE) and approved by the Ethics
Committee of the Biomedical Sciences Institute of
Abel Salazar, University of Porto.
Animal data such as weight, age, reproductive status
and previous administration of progestagens for oestrus
control, were obtained and registered and, for statistical
purposes, dogs were grouped into three categories: small
(<10 Kg), medium (10–23 Kg), and large breeds (>23 Kg)
according to the criteria of the Féderation Cynologique
Internationale (FCI). The clinical staging was assessed in
each animal, based in a complete physical examination,
three views thoracic radiographies, and a complete abdom-
inal ultrasound evaluation. Inclusion criteria were animals
with stage I to IV MMTs whose owners declined post-
operative adjuvant therapies. Exclusion criteria were ani-
mals with stage V MMTs and animals with a previous his-
tory of neoplastic disease.
Removed tumours were fixed in 10% neutral buffered
formalin for 48 h., measured in their largest diameter and
grouped in two categories: < 3 cm or ≥ 3 cm for statistical
purposes. Tumours < 1 cm were paraffin-embedded in one
block, while larger tumours were cut sequentially at 5 mm
intervals to provide tissue blocks representative of the en-
tire lesion. After dehydration and embedding in paraffin
wax, 3 μm sections were obtained from each block. Slides
were stained using haematoxylin and eosin (HE) and the
histological classification was performed by two patholo-
gists (FG and IA) using the criteria of the World HealthOrganization for the histological classification of mammary
tumours of domestic animals [3]. For statistical purposes,
tumours were grouped as: complex carcinomas, simple
carcinomas (solid, tubulopapillary, micropapillary and ana-
plastic), and other (mucinous carcinomas; spindle cell car-
cinomas; carcinosarcomas and carcinomas in benign
tumour). Representative sections were then selected for the
immunohistochemical studies.
When available, local and regional lymph nodes were
processed and examined as previously described [36].
The mitotic index was calculated and classified as low
(less than 10 mitotic figures per 10 hpf); moderate (10 to
19 per 10 hpf); and high (more than 20 per 10 hpf). Histo-
logical grading was determined, according to the Notting-
ham method [37], as Grade I (well differentiated), Grade II
(moderately differentiated) and Grade III (poorly differen-
tiated), as previously described in canine mammary
tumours [8]. Tumour growth was classified as expansive
(cohesive and well delimited mass pushing normal sur-
rounding tissues) or invasive (infiltrative growth or lymph-
atic or blood vessels invasion). The existence of necrosis
and squamous metaplasia, when detected, was registered.
When more than one malignant neoplasm were diag-
nosed (22 cases, including 4 animals that metastasized),
the tumour with the more aggressive clinical and histo-
pathological features (larger size, infiltrative growth,
higher grade) was selected.
Immunohistochemical study
Serial tumour sections were immunostained for Mind-
bomb homolog 1 (MIB1); VEGF; uPA; and TIMP-2 as
described, respectively, by Matos et al. (2006a) [13] and
Santos et al. (2010; 2011a,b) [35,38,39]. MMP-9 staining
was performed according to a previously described IHC
method [39] using the anti-MMP-9 (C-20) goat polyclonal
antibody (Santa Cruz Biotechnology) diluted 1:200 in TBS
with 5% BSA.
To determine the MIB-1 labelling index, the areas of
highest expression were selected and 1000 tumour cells
nuclei were counted in these areas at 400× magnification
with the help of a microscopic grid. The proportion of
stained nuclei was recorded as a percentage [13] and
tumours were grouped, for statistical purposes, according
to its mean value (40%). Regarding VEGF and TIMP-2
cytoplasmic immunoexpressions, tumours were grouped
using cut-off values of 50% and 25% positive cells, respect-
ively. The evaluation of the uPA and MMP-9 expressions
was based on the percentage of tumour-associated stromal
cells (fibroblasts) with cytoplasmic staining, using cut-off
values of 10% for uPA [39] and 50% for MMP-9.
Sections were examined independently by two obser-
vers (A.S. and A.M.) and when there was disagreement
(less than 5% of the cases) a consensus was reached
using a multi-head microscope.
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Dogs were evaluated before surgery, 3 weeks after surgery
and every 3 months thereafter for a 2-year period. Owners
were instructed to report and discuss with the researchers
any detected abnormalities, even if not obviously related to
the mammary gland tumours, at any time. Each evaluation
included a thorough physical examination, thoracic radio-
graphs (three views) and complete abdominal ultrasound.
Complete necropsies were performed, after owner consent,
in all dogs that died spontaneously or were euthanized,
and suspected metastases, when present, were histologi-
cally confirmed. Overall survival was calculated from the
date of surgery to the date of animal death/euthanasia due
to tumour metastasis. Disease-free survival was calculated
from the date of surgery to the date of detection of the first
local recurrence or distant metastases.
Statistical analysis
Survival curves were calculated using the Kaplan-Meier
method and the log-rank test was used to analyse the
significance of the differences between the groups
defined for each variable [40]. In the OS study, dogs
were censored if and when they died for causes unre-
lated to MMTs, were lost to follow-up, or were alive
24 months after surgery; in the DFS study, dogs were
censored if and when they were lost to follow-up, died
for causes unrelated to MMTs before developing recur-
rences or metastases, or were free of distant metastases
24 months after surgery. For each variable, the hazard of
recurrence or distant metastasis and the hazard of
tumour-related death were estimated by Cox regression
analysis [40]. Variables significantly associated with OS
or DFS in univariate analyses were included in the multi-
variable Cox proportional hazards model (forward step-
wise method) in order to select the outcome predictors
that retained significance, controlling for confounding
variables. Due to the high number of missing cases, RLN
status was not considered for inclusion on the multivari-
able model. The significance level was set at P < 0.05.
Statistical analysis was performed with the statistical
package PASW Statistics 18.0.
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